FOGELMAN MITCHELL K 4
4 · Abraxis BioScience, Inc. · Filed Oct 19, 2010
Insider Transaction Report
Form 4
FOGELMAN MITCHELL K
Acting Chief Financial Officer
Transactions
- Disposition to Issuer
Stock Option (Right to buy)
2010-10-15$33.21/sh−13,000$431,730→ 0 totalExercise: $39.93Exp: 2015-03-15→ Common Stock (13,000 underlying) - Disposition to Issuer
Common Stock
2010-10-15−7,000→ 0 total
Footnotes (2)
- [F1]Shares, subject to Restricted Stock Units disposed of pursuant to the Agreement and Plan of Merger, dated as of June 30, 2010, among Celgene Corporation ("Celgene"), Artistry Acquisition Corp. ("Merger Sub") and Abraxis BioScience, Inc. ("Abraxis"), whereby Merger Sub merged into Abraxis, with Abraxis continuing as the surviving company and a wholly owned subsidiary of Celgene (the "Merger"), in exchange for (i) an amount in cash equal to $73.14 and (ii) a contingent value right issued by Celgene.
- [F2]Pursuant to the Merger, this option, which was granted on March 15, 2010 and vests in four equal annual installments beginning on January 1, 2010, was cancelled in exchange for (i) a cash payment of $431,730.00, which represents the excess of $73.14 per share over the exercise price per share of this option and (ii) a contingent value right issued by Celgene.